Mostrar el registro sencillo del ítem

dc.contributor.authorRAYMOND, Stéphanie
dc.contributor.authorMAILLARD, Anne
dc.contributor.authorAMIEL, Corinne
dc.contributor.authorPEYTAVIN, Gilles
dc.contributor.authorTRABAUD, Mary Anne
dc.contributor.authorDESBOIS, Delphine
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBELLECAVE, Pantxika
dc.contributor.authorDELAUGERRE, Constance
dc.contributor.authorSOULIE, Cathia
dc.contributor.authorMARCELIN, Anne Geneviève
dc.contributor.authorDESCAMPS, Diane
dc.contributor.authorIZOPET, Jacques
dc.date.accessioned2023-07-18T08:29:57Z
dc.date.available2023-07-18T08:29:57Z
dc.date.issued2015
dc.identifier.issn0305-7453
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/183422
dc.description.abstractEnOBJECTIVES: Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc. This multicentre study aimed to characterize VF in patients treated with maraviroc. METHODS: We analysed 27 patients whose treatment failed between 2008 and 2011. They had been screened for HIV tropism before maraviroc initiation using population-based V3 genotyping. HIV-1 tropism and resistance of R5 viruses to maraviroc at VF and at baseline were determined retrospectively using an ultrasensitive recombinant virus assay (RVA). RESULTS: Viruses from 27 patients given maraviroc on the basis of the R5 genotype were characterized at the time of treatment failure. The RVA indicated that 12 patients harboured CXCR4-using viruses and 15 (56%) had pure R5 viruses at failure. One-third of those harbouring CXCR4-using viruses (4/12) were infected with R5X4/X4 viruses according to the RVA before maraviroc initiation. We analysed the phenotypic resistance to maraviroc of four patients harbouring R5 viruses at failure; two harboured viruses whose maximum percentage inhibition was reduced by 65%-90%, while the other two were infected with susceptible viruses. All patients had effective concentrations of drugs. CONCLUSIONS: Half of the maraviroc-treated patients who experienced VF harboured CXCR4-using viruses at failure, one-third of them were detected by a phenotypic method before maraviroc initiation. Phenotypic assessment of R5 virus resistance to CCR5 antagonists at failure could help optimize antiretroviral therapy
dc.language.isoen
dc.publisherOxford University Press (OUP)
dc.subject.enAdult
dc.subject.enAged
dc.subject.enAnti-Retroviral Agents
dc.subject.enAntiretroviral Therapy
dc.subject.enHighly Active
dc.subject.enCXCR4
dc.subject.enCyclohexanes
dc.subject.enDrug Resistance
dc.subject.enViral
dc.subject.enentry
dc.subject.enFemale
dc.subject.enHIV-1
dc.subject.enHIV-1 tropism determination
dc.subject.enHIV Infections
dc.subject.enHumans
dc.subject.enMale
dc.subject.enMiddle Aged
dc.subject.enphenotypic assay
dc.subject.enresistance to maraviroc
dc.subject.enRetrospective Studies
dc.subject.enTreatment Failure
dc.subject.enTriazoles
dc.subject.enViral Load
dc.subject.enViral Tropism
dc.title.enVirological failure of patients on maraviroc-based antiretroviral therapy
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jac/dkv026
dc.subject.halSciences du Vivant [q-bio]
bordeaux.page1858--1864
bordeaux.volume70
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue6
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
bordeaux.import.sourcehal
hal.identifierhal-01274888
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2015&rft.volume=70&rft.issue=6&rft.spage=1858--1864&rft.epage=1858--1864&rft.eissn=0305-7453&rft.issn=0305-7453&rft.au=RAYMOND,%20St%C3%A9phanie&MAILLARD,%20Anne&AMIEL,%20Corinne&PEYTAVIN,%20Gilles&TRABAUD,%20Mary%20Anne&rft.genre=article


Archivos en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem